Key result
Weekly administration of a murine-specific apoB ASO (ISIS 147764) produced dose-dependent reductions of hepatic apoB mRNA and plasma LDL by 60-90% and aortic atherosclerosis by 50-90%.
Why the study?
Does murine-specific apoB ASO (ISIS 147764) reduce plasma LDL and atherosclerosis in hypercholesterolemic LDLr deficient mice?
Does murine-specific apoB ASO (ISIS 147764) reduce plasma LDL and atherosclerosis in hypercholesterolemic LDLr deficient mice?
ASO-mediated suppression of apoB mRNA expression profoundly reduced plasma lipids and atherogenesis in LDLr(-/-) mice, suggesting potential therapeutic benefit for humans with impaired LDLr activity.
No takes yet. Share an insight, caveat, or question.
Supports preclinical apoB ASO efficacy in LDLr(-/-) mice; leaves open translation to human hypercholesterolemia.
Mullick et al. (2011) studied Hypercholesterolemia and atherosclerosis. Murine-specific apoB ASO (ISIS 147764) vs. Control ASOs and saline was evaluated on Hepatic apoB mRNA, plasma LDL, and aortic atherosclerosis. Weekly administration of a murine-specific apoB ASO (ISIS 147764) produced dose-dependent reductions of hepatic apoB mRNA and plasma LDL by 60-90% and aortic atherosclerosis by 50-90%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: